Stephen Hanauer to Delayed-Action Preparations
This is a "connection" page, showing publications Stephen Hanauer has written about Delayed-Action Preparations.
Connection Strength
0.496
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
Score: 0.139
-
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3.
Score: 0.087
-
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34.
Score: 0.077
-
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
Score: 0.067
-
New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3.
Score: 0.053
-
Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51.
Score: 0.029
-
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug; 88(8):1188-97.
Score: 0.028
-
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5.
Score: 0.008
-
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304.
Score: 0.008